Literature DB >> 16010174

A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials.

Catherine Boileau1, Julie Bruneau, Hicham Al-Nachawati, François Lamothe, Jean Vincelette.   

Abstract

OBJECTIVE: The main goal of this study was to construct a prognostic model for HIV seroconversion among injection drug users (IDUs) using easy-to-measure risk indicators.
DESIGN: Cox proportional hazards regression modeling was used for risk stratification in a heterogeneous population of IDUs with regards to HIV risk-taking behaviors.
METHODS: Subjects were recruited in a prospective cohort of IDUs followed between September 1992 and October 2001. A total of 1602 men, seronegative at enrollment with at least 1 follow-up visit, were included in the analyses. Only variables that consistently predict HIV seroconversion in several settings were considered. The final model was used to assign a risk score for each participant.
RESULTS: Three risk indicators were included in the risk score to predict HIV seroconversion: unstable housing, average cocaine injections per day, and having shared a syringe with a known HIV-positive partner. Kaplan-Meier survival functions were generated and risk score values stratified in 3 groups. HIV incidence rates per 100 person-years were as follows: 0.91 (95% CI, 0.55-1.52) for the low-risk group, 3.10 (95% CI, 2.49-3.84) for the moderate-risk group, and 7.82 (95% CI, 6.30-9.73) for the high-risk group (log-rank P value < 0.0001).
CONCLUSION: If validated in other settings, this risk score may improve the prediction of outcome and allow more accurate stratification in clinical trials.

Entities:  

Mesh:

Year:  2005        PMID: 16010174     DOI: 10.1097/01.qai.0000153424.56379.61

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

1.  Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users.

Authors:  Costin Tomescu; Fuh-Mei Duh; Michael A Lanier; Angela Kapalko; Karam C Mounzer; Maureen P Martin; Mary Carrington; David S Metzger; Luis J Montaner
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

2.  S100A14 Is Increased in Activated NK Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-NK Crosstalk.

Authors:  Krystal Colón; David W Speicher; Peter Smith; Mack Taylor; David S Metzger; Luis J Montaner; Costin Tomescu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

3.  Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in montreal, Canada: a 16-year longitudinal study.

Authors:  Julie Bruneau; Mark Daniel; Michal Abrahamowicz; Geng Zang; François Lamothe; Jean Vincelette
Journal:  Am J Epidemiol       Date:  2011-03-01       Impact factor: 4.897

4.  Predicting partner HIV testing and counseling following a partner notification intervention.

Authors:  Lillian B Brown; William C Miller; Gift Kamanga; Jay S Kaufman; Audrey Pettifor; Rosalie C Dominik; Naomi Nyirenda; Pearson Mmodzi; Clement Mapanje; Francis Martinson; Myron S Cohen; Irving F Hoffman
Journal:  AIDS Behav       Date:  2012-07

Review 5.  Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN).

Authors:  C Tomescu; S Abdulhaqq; L J Montaner
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

6.  Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls.

Authors:  Costin Tomescu; Kelly E Seaton; Peter Smith; Mack Taylor; Georgia D Tomaras; David S Metzger; Luis J Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2015-03-01       Impact factor: 3.731

7.  Not all injection drug users are created equal: heterogeneity of HIV, hepatitis C virus, and hepatitis B virus infection in Georgia.

Authors:  Mark H Kuniholm; Malvina Aladashvili; Carlos Del Rio; Ketavan Stvilia; Nino Gabelia; Rohit A Chitale; Tengiz Tsertsvadze; Kenrad E Nelson
Journal:  Subst Use Misuse       Date:  2008       Impact factor: 2.164

8.  Prediction of HIV acquisition among men who have sex with men.

Authors:  Timothy W Menza; James P Hughes; Connie L Celum; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2009-09       Impact factor: 2.830

9.  Service priorities and unmet service needs among people living with HIV/AIDS: results from a nationwide interview of HIV/AIDS housing organizations.

Authors:  Carter A Lennon; Jennifer A Pellowski; Angela C White; Seth C Kalichman; David J Finitsis; Viana Turcios-Cotto; Alefiyah Pishori; Nicole M Overstreet; Dominica Hernandez; Ann Kane; David M Kelly; Gertrude A Lanouette
Journal:  AIDS Care       Date:  2013-01-10

10.  Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use.

Authors:  Costin Tomescu; Krystal Colon; Peter Smith; Mack Taylor; Livio Azzoni; David S Metzger; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2020-12-02       Impact factor: 6.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.